Australia markets closed

Cerevel Therapeutics Holdings, Inc. (CERE)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
34.55+0.12 (+0.35%)
At close: 04:00PM EST
34.55 0.00 (0.00%)
After hours: 04:00PM EST
Full screen
Trade prices are not sourced from all markets
Previous close34.43
Bid0.00 x 1000
Ask0.00 x 1000
Day's range33.83 - 34.78
52-week range19.86 - 41.46
Avg. volume535,168
Market cap5.401B
Beta (5Y monthly)1.47
PE ratio (TTM)N/A
EPS (TTM)-1.71
Earnings date27 Feb 2023 - 03 Mar 2023
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est40.82
  • GlobeNewswire

    Cerevel Therapeutics to Present at 41st Annual J.P. Morgan Healthcare Conference and Provide Pipeline Update

    Initiated Phase 1 healthy volunteer trial to support development of emraclidine in Alzheimer’s disease psychosis in Q4 2022; second potential indication as a once-daily treatment Phase 2 proof-of-concept darigabat panic disorder trial to be initiated in Q2 2023 Multiple data readouts and cash runway into 2025 to support advancement of diverse pipeline of novel neuroscience drug candidates Cerevel presentation to take place on January 10 at 8:15 a.m. PT/11:15 a.m. ET CAMBRIDGE, Mass., Jan. 09, 20

  • GlobeNewswire

    Cerevel Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

    CAMBRIDGE, Mass., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Cerevel Therapeutics, (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced that chairperson and chief executive officer Tony Coles, M.D., will present at the upcoming 41st Annual J.P. Morgan Healthcare Conference. Dr. Coles will be joined by additional members of the executive team for the question-and-answer portion of the presentation. Date: Tuesday, January 10, 2023 Form

  • Simply Wall St.

    Are Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE) Investors Paying Above The Intrinsic Value?

    Today we'll do a simple run through of a valuation method used to estimate the attractiveness of Cerevel Therapeutics...